Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases

• Published in: Cancer medicine (Malden, MA) Vol. 12; no. 16; pp. 16972 - 16984
• Main Authors: Iriyama, Chisako, Murate, Kenichiro, Iba, Sachiko, Okamoto, Akinao, Goto, Naoe, Yamamoto, Hideyuki, Kato, Toshiharu, Mihara, Keichiro, Miyama, Takahiko, Hattori, Keiko, Kajiya, Ryoko, Okamoto, Masataka, Mizutani, Yasuaki, Yamada, Seiji, Tsukamoto, Tetsuya, Hirose, Yuichi, Mutoh, Tatsuro, Watanabe, Hirohisa, Tomita, Akihiro
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.08.2023; John Wiley and Sons Inc; Wiley
• Subjects: Biopsy; CD79B; Central nervous system; central nervous system lymphoma; Cerebrospinal fluid; Demyelinating diseases; Demyelination; Encephalitis; genetic mutations; Hemoglobin; Infectious diseases; Laboratories; liquid biopsy; Lymphoma; Meningitis; Multiple sclerosis; Mutation; MYD88; MyD88 protein; Neuroimaging; Peripheral blood; Tumors; Japan; CD79B; genetic mutations; central nervous system lymphoma; MYD88; liquid biopsy
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.6329

Background Distinguishing between central nervous system lymphoma (CNSL) and CNS infectious and/or demyelinating diseases, although clinically important, is sometimes difficult even using imaging strategies and conventional cerebrospinal fluid (CSF) analyses. To determine whether detection of genetic mutations enables differentiation between these diseases and the early detection of CNSL, we performed mutational analysis using CSF liquid biopsy technique. Methods In this study, we extracted cell‐free DNA from the CSF (CSF‐cfDNA) of CNSL (N = 10), CNS infectious disease (N = 10), and demyelinating disease (N = 10) patients, and performed quantitative mutational analysis by droplet‐digital PCR. Conventional analyses were also performed using peripheral blood and CSF to confirm the characteristics of each disease. Results Blood hemoglobin and albumin levels were significantly lower in CNSL than CNS infectious and demyelinating diseases, CSF cell counts were significantly higher in infectious diseases than CNSL and demyelinating diseases, and CSF‐cfDNA concentrations were significantly higher in infectious diseases than CNSL and demyelinating diseases. Mutation analysis using CSF‐cfDNA detected MYD88L265P and CD79Y196 mutations in 60% of CNSLs each, with either mutation detected in 80% of cases. Mutual existence of both mutations was identified in 40% of cases. These mutations were not detected in either infectious or demyelinating diseases, and the sensitivity and specificity of detecting either MYD88/CD79B mutations in CNSL were 80% and 100%, respectively. In the four cases biopsied, the median time from collecting CSF with the detected mutations to definitive diagnosis by conventional methods was 22.5 days (range, 18–93 days). Conclusions These results suggest that mutation analysis using CSF‐cfDNA might be useful for differentiating CNSL from CNS infectious/demyelinating diseases and for early detection of CNSL, even in cases where brain biopsy is difficult to perform. Genetic analyses using cerebrospinal fluid cell‐free DNA (CSF‐cfDNA) (liquid biopsy) is a useful strategy for distinguishing central nervous system lymphoma (CNSL) from CNS infectious/demyelinating diseases. Genetic analysis using CSF‐cfDNA can be contribute to earlier detection of CNSL than conventional methods.